Applied DNA Sciences, Inc. (APDN)
USD 0.89
(10.37%)
USD 0.89
(10.37%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 330.02 Thousand USD | -45.2% |
| 2022 | 602.24 Thousand USD | -56.04% |
| 2021 | 1.36 Million USD | 175.44% |
| 2020 | 497.36 Thousand USD | 248.71% |
| 2019 | 142.62 Thousand USD | -35.57% |
| 2018 | 221.36 Thousand USD | -32.19% |
| 2017 | 326.46 Thousand USD | 9.64% |
| 2016 | 297.75 Thousand USD | 29775800.0% |
| 2015 | 1.00 USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 335.94 Thousand USD | -10.96% |
| 2024 Q1 | 377.29 Thousand USD | 14.32% |
| 2024 Q3 | 469.87 Thousand USD | 39.87% |
| 2023 Q3 | 276.42 Thousand USD | -24.49% |
| 2023 Q4 | 330.02 Thousand USD | 19.39% |
| 2023 FY | 330.02 Thousand USD | -45.2% |
| 2023 Q1 | 477.01 Thousand USD | -20.79% |
| 2023 Q2 | 366.08 Thousand USD | -23.25% |
| 2022 Q2 | 1.41 Million USD | 8.48% |
| 2022 Q1 | 1.3 Million USD | -5.06% |
| 2022 FY | 602.24 Thousand USD | -56.04% |
| 2022 Q4 | 602.24 Thousand USD | -48.63% |
| 2022 Q3 | 1.17 Million USD | -16.91% |
| 2021 Q4 | 1.36 Million USD | 219.25% |
| 2021 Q2 | 720.53 Thousand USD | 32.58% |
| 2021 Q3 | 429.11 Thousand USD | -40.45% |
| 2021 Q1 | 543.46 Thousand USD | 9.27% |
| 2021 FY | 1.36 Million USD | 175.44% |
| 2020 Q2 | 88.94 Thousand USD | 7.57% |
| 2020 Q3 | 444.64 Thousand USD | 399.93% |
| 2020 Q1 | 82.68 Thousand USD | -42.03% |
| 2020 Q4 | 497.36 Thousand USD | 11.86% |
| 2020 FY | 497.36 Thousand USD | 248.71% |
| 2019 Q1 | 225.28 Thousand USD | 1.77% |
| 2019 Q2 | 314.67 Thousand USD | 39.68% |
| 2019 FY | 142.62 Thousand USD | -35.57% |
| 2019 Q3 | 309.74 Thousand USD | -1.57% |
| 2019 Q4 | 142.62 Thousand USD | -53.95% |
| 2018 Q2 | 293.83 Thousand USD | -6.45% |
| 2018 FY | 221.36 Thousand USD | -32.19% |
| 2018 Q4 | 221.36 Thousand USD | -25.03% |
| 2018 Q3 | 295.27 Thousand USD | 0.49% |
| 2018 Q1 | 314.08 Thousand USD | -3.79% |
| 2017 FY | 326.46 Thousand USD | 9.64% |
| 2017 Q4 | 326.46 Thousand USD | -13.29% |
| 2017 Q3 | 376.52 Thousand USD | 6.49% |
| 2017 Q2 | 353.58 Thousand USD | 9.36% |
| 2017 Q1 | 323.32 Thousand USD | 8.59% |
| 2016 Q3 | 126.87 Thousand USD | 0.0% |
| 2016 FY | 297.75 Thousand USD | 29775800.0% |
| 2016 Q4 | 297.75 Thousand USD | 134.7% |
| 2016 Q1 | - USD | -100.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 Q1 | 1.00 USD | 0.0% |
| 2015 FY | 1.00 USD | 0.0% |
| 2015 Q4 | 1.00 USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | -100.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q3 | 1.00 USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | -100.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | -100.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | 1.00 USD | 0.0% |
| 2013 Q4 | - USD | -100.0% |
| 2013 Q1 | 1.00 USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | 1.00 USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 Q2 | 89.33 Thousand USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | -100.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 100.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q4 | -8419.00 USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Aspira Women's Health Inc. | 227 Thousand USD | -45.386% |
| Biodesix, Inc. | 1.4 Million USD | 76.427% |
| BioNexus Gene Lab Corp. | 1.13 Million USD | 70.994% |
| bioAffinity Technologies, Inc. | 18.48 Thousand USD | -1685.474% |
| bioAffinity Technologies, Inc. | 18.48 Thousand USD | -1685.474% |
| Bionano Genomics, Inc. | 22.89 Million USD | 98.558% |
| CareDx, Inc | 19.47 Million USD | 98.305% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 7.94 Million USD | 95.845% |
| DarioHealth Corp. | 5.06 Million USD | 93.48% |
| Exact Sciences Corporation | 127.47 Million USD | 99.741% |
| Fulgent Genetics, Inc. | 5.82 Million USD | 94.336% |
| Guardant Health, Inc. | 61.94 Million USD | 99.467% |
| ICON Public Limited Company | 1.00 USD | -33002600.0% |
| IDEXX Laboratories, Inc. | 380.28 Million USD | 99.913% |
| Illumina, Inc. | 587 Million USD | 99.944% |
| Intelligent Bio Solutions Inc. | 777.53 Thousand USD | 57.555% |
| iSpecimen Inc. | - USD | -Infinity% |
| Standard BioTools Inc. | 20.53 Million USD | 98.393% |
| MDxHealth SA | 2.77 Million USD | 88.124% |
| 23andMe Holding Co. | 12.46 Million USD | 97.352% |
| Medpace Holdings, Inc. | 1.00 USD | -33002600.0% |
| Myriad Genetics, Inc. | 20.1 Million USD | 98.358% |
| Mainz Biomed B.V. | 613.63 Thousand USD | 46.218% |
| ENDRA Life Sciences Inc. | 2.62 Million USD | 87.417% |
| NeoGenomics, Inc. | 24.15 Million USD | 98.634% |
| Neogen Corporation | 189.26 Million USD | 99.826% |
| Inotiv, Inc. | 56.1 Million USD | 99.412% |
| Natera, Inc. | 40.75 Million USD | 99.19% |
| OpGen, Inc. | 1.00 USD | -33002600.0% |
| OPKO Health, Inc. | 65.69 Million USD | 99.498% |
| Psychemedics Corporation | 1.00 USD | -33002600.0% |
| Prenetics Global Limited | 3.12 Million USD | 89.445% |
| Prenetics Global Limited | 3.12 Million USD | 89.445% |
| Precipio, Inc. | 384 Thousand USD | 14.055% |
| Personalis, Inc. | 5.66 Million USD | 94.17% |
| RadNet, Inc. | 1.00 USD | -33002600.0% |
| Sera Prognostics, Inc. | - USD | -Infinity% |
| Sotera Health Company | 51.98 Million USD | 99.365% |
| Neuronetics, Inc. | 8.09 Million USD | 95.922% |
| Star Equity Holdings, Inc. | 3.42 Million USD | 90.35% |
| Star Equity Holdings, Inc. | 3.42 Million USD | 90.35% |
| Trinity Biotech plc | 19.93 Million USD | 98.344% |
| T2 Biosystems, Inc. | 4.81 Million USD | 93.152% |
| Twist Bioscience Corporation | 32.06 Million USD | 98.971% |
| Exagen Inc. | 2.87 Million USD | 88.505% |